Edition:
United States

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

65.57EUR
9 Dec 2016
Change (% chg)

€0.47 (+0.72%)
Prev Close
€65.10
Open
€65.12
Day's High
€66.29
Day's Low
€64.88
Volume
152,081
Avg. Vol
75,195
52-wk High
€66.29
52-wk Low
€45.31

IPN.PA

Chart for IPN.PA

About

Ipsen SA is a France-based pharmaceutical company that produces a range of various types of drugs. Its portfolio includes pharmaceutical products divided into four targeted therapeutic areas: Neurology, Endocrinology, Uro-Oncology and Primary Care. In the Neurology segment the Company offers a product called Dysport, in... (more)

Overall

Beta: 0.48
Market Cap(Mil.): €5,428.52
Shares Outstanding(Mil.): 83.39
Dividend: 0.85
Yield (%): 1.31

Financials

  IPN.PA Industry Sector
P/E (TTM): 23.07 29.74 30.35
EPS (TTM): 2.82 -- --
ROI: 14.45 15.90 15.27
ROE: 19.51 17.00 16.60

BRIEF-Ipsen Q3 sales up 12.2 pct at 390.6 mln euros

* Reports 12.2% sales growth for the third qtr Of 2016 and raises full year guidance

Oct 26 2016

BRIEF-Ipsen and Exelixis announce positive results from Phase 2 CABOSUN trial of cabozantinib

* Ipsen and its partner Exelixis announce positive results from Phase 2 CABOSUN Trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

Oct 10 2016

BRIEF-Ipsen announces data presentations at 2016 ESMO congress

* Ipsen announces data presentations of Cabozantinib, Lanreotide and Telotristat Ethyl at the european society for medical oncology (ESMO) 2016 congress Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Sep 27 2016

BRIEF-European Commission approves Ipsen's Cabometyx tablets

* European Commission approves Ipsen's Cabometyx (cabozantinib) tablets for the treatment of advanced Renal Cell Carcinoma (RCC) in adults following prior Vascular Endothelial Growth Factor (VEGF)-targeted therapy

Sep 14 2016

Dorsey's Square reports 41.5 percent jump in quarterly revenue

Mobile payments company Square Inc on Wednesday reported a 41.5 percent jump in revenue and diminishing losses as more large merchants make sales using Square's technology, a sign the company has moved beyond serving only pop-up shops and food trucks.

Aug 03 2016

BRIEF-Ipsen announces FDA approval of dysport for the treatment of lower limb spasticity in children

* Ipsen announces FDA approval of dysport (abobotulinumtoxina) for injection for the treatment of lower limb spasticity in children aged two and older Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Aug 01 2016

BRIEF-Supplemental application filed for Ipsen's Somatuline in Japan

* Says its Janapese partner Teijin Pharma has filed a supplemental application with Pharmaceuticals and Medical Devices Agency to use Ipsen's subcutaneous drug Somatuline (lanreotide) for the treatment of neuroendocrine tumors (NETs) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 28 2016

UPDATE 1-Ipsen shares jump after raised guidance for specialty care

PARIS, July 28 Shares of French drugmaker Ipsen are up more than 6 percent on Thursday after the company said it had raised its full-year guidance for specialty care sales growth on the back of first half results.

Jul 28 2016

BRIEF-Ipsen and Exelixis receive positive CHMP opinion for Cabometyx

* Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx (cabozantinib) for treatment of advanced renal cell carcinoma in adults

Jul 22 2016

BRIEF-Ipsen SA says David Meek appointed as CEO

* Marc De Garidel will assume role of non-executive chairman and will continue to serve board of directors

Jul 11 2016

Earnings vs. Estimates